Afucosylated anti-FGFR2IIIB antibodies
US11235059B2 · kind B2 · utility
0Cited by
30References
59Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 6, 2018 |
| Grant date | Feb 1, 2022 |
| Priority date | — |
| Expiry date | Nov 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.